{"ModuleTitle": "Company Description", "CompanyName": "MannKind Corporation", "Symbol": "MNKD", "Address": "30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE, California, 91362, United States of America", "Phone": "818-661-5000", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "Unless the context requires otherwise, the words \"MannKind,\" \"we,\" \"Company,\"\r\n\"us\" and \"our\" refer to MannKind Corporation and its subsidiaries.\r\n\r\nWe are a biopharmaceutical company focused on the development and\r\ncommercialization of inhaled therapeutic products for patients with diseases\r\nsuch as diabetes and pulmonary arterial hypertension. Our only approved product,\r\nAfrezza (insulin human) Inhalation Powder, is an ultra rapid-acting inhaled\r\ninsulin that was approved by the U.S. Food and Drug Administration (\"FDA\") in\r\nJune 2014. Afrezza became available by prescription in U.S. retail pharmacies in\r\nFebruary 2015. According to the Centers for Disease Control and Prevention,\r\n30.3 million people in the United States had diabetes in 2015. Globally, the\r\nInternational Diabetes Federation has estimated that approximately 463 million\r\nadults had diabetes in 2019 and approximately 700 million will have diabetes by\r\n2045.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f25%2f0001564590-20-006198.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "David M. Kendall", "title": "Chief Medical Officer"}, {"name": "Joseph Kocinsky", "title": "Chief Technology Officer"}, {"name": "Michael E. Castagna", "title": "Chief Executive Officer & Director"}, {"name": "Steven Binder", "title": "CFO & Principal Accounting Officer"}], "Number_of_employees": [], "Subsidiaries": ["NO INFO"]}